The total return over the past 12 months is -21.12% vs. +16.94% for the S&P 500. So far it's up -29.26% this year. Includes price appreciation + reinvested dividends.
| Category | 1Y (TTM) | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Price CAGR | (21.12%) | +52.23% | +2.24% | N/A | N/A | N/A |
| Total Return CAGR | (21.12%) | +52.23% | +2.24% | N/A | N/A | N/A |
| Revenue CAGR | +22.56% | +5.15% | (0.58%) | N/A | N/A | N/A |
| Net Income CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| EPS CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Dividends CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
Visualize historical growth rates over rolling horizons. Use the dropdown to select different metric vectors.
Aquestive Therapeutics, Inc. (AQST)
| Year | Start price | End price | AQST Return | SPY Return | Outperformance |
|---|---|---|---|---|---|
| 2026(YTD) | $6.46 | $4.57 | (29.26%) | +14.51% | (43.77%) |
| 2025 | $3.56 | $6.46 | +81.46% | +17.72% | +63.74% |
| 2024 | $2.02 | $3.56 | +76.24% | +24.89% | +51.35% |
| 2023 | $0.90 | $2.02 | +123.92% | +26.19% | +97.73% |
| 2022 | $3.89 | $0.90 | (76.81%) | (18.17%) | (58.64%) |
| 2021 | $5.35 | $3.89 | (27.29%) | +28.74% | (56.03%) |
| 2020 | $5.82 | $5.35 | (8.08%) | +18.37% | (26.45%) |
| 2019 | $6.30 | $5.82 | (7.62%) | +31.22% | (38.84%) |
Start and end prices are split-adjusted closing prices. Total return includes reinvested dividends, so it can differ from the price change.
